

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/02, 9/06, C12Q 1/26	A1	(11) International Publication Number: WO 00/18891 (43) International Publication Date: 6 April 2000 (06.04.00)
(21) International Application Number: PCT/NZ99/00160 (22) International Filing Date: 24 September 1999 (24.09.99) (30) Priority Data: 332085 25 September 1998 (25.09.98) NZ (71) Applicant (for all designated States except US): GLYCOX CORPORATION LIMITED [NZ/NZ]; Bowden Impey & Sage, 470 Parnell Road, Auckland 1 (NZ). (72) Inventor; and (75) Inventor/Applicant (for US only): BAKER, John, Richard [NZ/NZ]; 61 Hunter Road, RD 2, Henderson, Auckland 1 (NZ). (74) Agents: CALHOUN, Douglas, C. et al.; A J Park & Son, Huddart Parker Building, 6th floor, Post Office Square, P.O. Box 949, Wellington 6015 (NZ).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: FRUCTOSAMINE OXIDASE ASSAY: METHODS AND MATERIALS (57) Abstract Methods whereby, by reference to fructosamine oxidase activity in blood plasma of a patient or patients, the risk of diabetes associated vascular complications can be assessed, candidate fructosamine oxidase inhibitors and/or antagonists can be identified or tested and the inhibition and/or antagonism of the fructosamine oxidase inhibition and/or antagonism of a patient can be assessed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

FRUCTOSAMINE OXIDASE ASSAY: METHODS AND MATERIALS

THE CURRENT INVENTION

The present invention relates to methods and materials for the assay of
5 fructosamine oxidase enzyme in patients and particularly but not solely those
predisposed to or with diabetes mellitus.

Diabetes mellitus is a common disease characterised by serious long-term
vascular complications. Diabetic individuals have a 25-fold increase in the risk of
blindness, a 20-fold increase in the risk of renal failure, a 20-fold increase in the risk of
10 amputation as a result of gangrene, and a 2- to 6-fold increased risk of coronary artery
disease and ischemic brain damage. See, Klein R, Klein B, Davis M, DeMets D.
Diabetes Care 8:311-5 (1985). Almost half those diagnosed as diabetic before the age
of 31 years, die before they reach 50 years largely as a result of cardiovascular or renal
complications, often with many years of crippling and debilitating disease beforehand.
15 See, Deckert T, Poulsen J, Larsen M. *Diabetologia* 14:363-70 (1978).

Elevated blood glucose levels are now regarded as *causative* of diabetic
complications based on results of the Diabetes Complications and Control Trial (DCCT)
and the United Kingdom Prospective Diabetes Study (UKPDS). See, The Diabetes
Control and Complications Trial Research Group. *N Eng J Med.* 379:977-85 (1993) and
20 *Lancet* 352:837-53 (1998). The DCCT and the UKPDS have both demonstrated that the
development of complications of diabetes are related with degree of hyperglycaemia
and that long-term outcome may be ameliorated by rigorous treatment. After controlling
for current HbA_{1c} levels, the development of micro vascular complications in DCCT
patients was strongly correlated with the degree of nonenzymatic glycation of structural
25 proteins such as skin collagen, but not with advanced glycation end product (AGE)
markers such as pentosidine, carboxymethyllysine, and tissue fluorescence (V Monnier -
personal communication). These findings imply that the nonenzymatic glycation of
tissue proteins has greater pathophysiological importance than AGE formation.

Many of the features of diabetic vascular disease may also be attributed to
30 oxidative stress, defined as an increase in the steady-state level of reactive oxygen or
oxygen radicals in a biological system See, Baynes JW. *Diabetes* 40:405-12 (1991). For

example, superoxide anions increase intracellular calcium which modulates the activity of nitric oxide synthase in the endothelium. Nitric oxide is a potent vasodilator and it has been implicated in the vascular dysfunction of early diabetes See, Ido Y, Kilo C, Williamson JR. *Nephrol Dial Transplant* 11 Suppl 5:72-5 (1996). Reactive oxygen species precipitate a drastic dose-dependent decrease in *de novo* synthesis of heparan sulphate proteoglycans leading to a reduction in anionic sites on the basement membrane and to an increased permeability to positively charged proteins such as albumin See, Kashira N, Watanabe Y, Makin H, Wallner EI, & Kanwar YS. *Proc Natl Acad Sci USA* 89:6309-13 (1992). Such leaky capillaries manifest clinically as background retinopathy and microalbuminuria. Microalbuminuria, in turn, is a recognised risk factor both for diabetic nephropathy in IDDM and for coronary artery disease and sudden death in elderly NIDDM See, Mogensen CE, Christensen CK. *N Eng J Med* 311:89-93 (1984) & Mogensen CE, Damsgaard EM, Froland A, et al *Clin Nephrol* 38 (suppl 1):s28-39 (1992).

Once natural anti-oxidant defences are exceeded, there is the potential for hydroxyl radical generation from superoxide via a copper catalysed Haber-Weiss reaction See, Halliwell B & Gutteridge JMC "Free radicals in Biology and Medicine" Clarendon Press, Oxford (pp. 136-76 1989). Hydroxyl radicals are extremely reactive species that cause serious site-specific damage.

Oxygen radicals have also been implicated in the oxidative modification of low density lipoprotein (LDL) See, Witztum JL. *Br Heart J* 69; S12-S18 (1993). Oxidised LDL is a specific risk factor for atherosclerosis, binding with a scavenger receptor on tissue macrophages leading to the formation of foam cells and to cholesteryl ester accumulation in the intimal fatty streak, a feature of atheromatous plaque formation.

To date, the source of the oxidative stress in diabetes has not been identified. I have isolated a novel extracellular enzyme which catalyses the elimination of fructosamines from glycated protein. The existence of this enzyme has not previously been recognised in the world literature. The reaction is important because fructosamine is the precursor of all the Maillard products. Based on its high specificity for glycated protein substrates and its use of oxygen as acceptor, the enzyme may be classified as **fructosamine oxidase 1.5.3** See, Enzyme nomenclature, Recommendations of the

Nomenclature Committee of the International Union of Biochemistry, Academic Press, London pp. 19-22, (1979). Fructosamine oxidase is a metalloenzyme with copper and quinone cofactors. Reaction products are free unglycated protein, α -dicarbonyl sugar, and superoxide (Figure 1).

5

SUMMARY OF THE INVENTION

The existence of the fructosamine oxidase enzyme has not previously been recognised in the world literature. This is a novel enzyme. The present invention relates to methods of monitoring fructosamine oxidase inhibition and/or antagonism of patients, methods for testing or identifying fructosamine oxidase inhibitors, methods of screening patients to determine patients at risk to vascular (particularly microvascular) damage and methods of identifying those individuals who will benefit by treatment with fructosamine oxidase inhibitors and/or antagonists, methods of determining fructosamine oxidase levels in a mammal, methods of determining blood plasma fructosamine oxidase levels in a diabetic individual or a suspected individual, methods of assaying blood serum or blood plasma *in vitro* for fructosamine oxidase and to related methods and procedures.

In one aspect the invention consists in a method of determining fructosamine oxidase activity in blood plasma of mammalian patients or a mammalian patient to determine patients or a patient at risk to vascular damage, which method comprises determining the levels of fructosamine oxidase and/or the superoxide reaction product of fructosamine oxidase and/or any other oxygen free radical product of fructosamine oxidase in the population of patients and making the determination dependant upon such levels.

Preferably the patients are humans suffering from or predisposed to diabetes.

Preferably said fructosamine oxidase activity is measured in blood taken from each patient.

Preferably the measurement conducted *in vitro* is of the superoxide reaction product or any other oxygen free radical product of fructosamine oxidase.

Preferably at risk patients are or an at risk patient is then treated *inter alia* to inhibit and/or to antagonise fructosamine oxidase.

Accordingly, in another aspect the present invention consists in a method of screening mammalian patients (preferably humans suffering from or predisposed to diabetes) to determine patients at risk to vascular (particularly microvascular) damage, which method comprises determining the levels of fructosamine oxidase and/or the
5 superoxide reaction product (or any other oxygen free radical product) of fructosamine oxidase in the population of patients and making the determination dependant upon such levels.

Preferably said screening is of blood taken from each patient.

Preferably the measurement conducted *in vitro* is of the superoxide reaction
10 product (or any other oxygen free radical product) of fructosamine oxidase.

Preferably at risk patients are then treated inter alia to inhibit and/or to antagonise the fructosamine oxidase.

Preferably the procedure is substantially as hereinafter described.

In still a further aspect, the present invention consists in a method of identifying
15 those individuals who will benefit by treatment with fructosamine oxidase inhibitors and/or antagonists, which method comprises testing an individual or a group of individuals for fructosamine oxidase in their blood directly or by reference to the superoxide reaction product (or any other oxygen free radical product) of fructosamine oxidase.

20 Preferably at risk patients are then treated inter alia to inhibit and/or to antagonise the fructosamine oxidase.

Preferably the procedure is substantially as hereinafter described.

In still a further aspect, the present invention consists in a method of monitoring fructosamine oxidase inhibition and/or antagonism of a patient which comprises or
25 includes testing (directly or indirectly) the fructosamine oxidase level of such patient.

Preferably such testing is by reference to the superoxide reaction product (or any other oxygen free radical product of fructosamine oxidase) in the blood of the patient.

Preferably each of the methods involves a determination of a particular level attributed to fructosamine oxidase and/or the reaction products referred to in
30 comparison to such level or levels of a patient or patients (as the case may be) who is or are not at risk to such vascular damage, or will not benefit by treatment with

fructosamine oxidase inhibitors and/or antagonists or have no need for fructosamine oxidase inhibition and/or antagonism.

In another aspect the invention consists in a method of testing and/or identifying fructosamine oxidase inhibitors or a fructosamine oxidase inhibitor which comprises
5 measuring the effect a candidate substance has or candidate substances have on one or more of the quinone co-factor, or the copper co-factor of fructosamine oxidase.

In yet another aspect the invention consists in a method of identifying a candidate substance for trial for the amelioration of diabetes induced vascular damage in a mammal which comprises testing such a substance for fructosamine oxidase
10 inhibition and/or antagonism and choosing to trial the substance where

(i) it has a specificity for such an enzyme or its co-factors

and

(ii) it has an effectiveness for such inhibition and/or antagonism at dosage levels not known to be toxic or contraindicated in such a mammal.

15 In still a further aspect the present invention consists in the measurement *in vitro* of the superoxide reaction product (and/or any other oxygen free radical product) of fructosamine oxidase in the blood of a mammal by exploiting its reductant properties or its oxidant properties or by enzymatic means.

In one preferred form said measurement procedure involves (preferably at a pH
20 7 to 8 (most preferably at pH greater than 7.5)) the disabling of the superoxide scavenging mechanism (such as superoxide dismutase) (SOD) [e.g. using potassium cyanide or (more preferably) by pretreatment with antihuman CuZn SOD antisera] and then exposure [e.g. by addition] to a suitable fructosamine oxidase substrate [e.g. glycated bovine serum albumin modified to eliminate copper chelating activity which
25 might disable the fructosamine oxidase].

Preferably the measurement following from the preferred procedure described involves a consideration [e.g. measurement] of an absorbance change, chemiluminescent change, or some other characterising change in an indicator of the modified sample.

30 In still a further aspect the present invention consists in a method of determining the fructosamine oxidase levels in a mammal (human or non-human) which at least

includes procedures as previously set forth.

In still a further aspect the present invention consists in a method of determining blood plasma fructosamine oxidase levels in a diabetic individual or a suspected diabetic individual which comprises at least steps of a method as previously set forth.

5 In still a further aspect the present invention consists in a method of assaying blood serum or blood plasma *in vitro (directly and/or indirectly)* for fructosamine oxidase which involves at least one or more of the steps or procedures hereinbefore described and/or hereinafter described.

10 In still a further aspect the present invention consists in a blood serum or blood plasma sample of a patient in which the superoxide scavenging mechanisms therein have been disabled and the pH is in the range from 7 to 8.

Preferably said sample also includes or has been modified by exposure to a suitable fructosamine oxidase substrate.

15 Preferably said fructosamine oxidase substrate is glycated bovine serum albumin modified to eliminate copper chelating activity which might disable fructosamine oxidase.

In still a further aspect the present invention consists in the use of a sample in accordance with the present invention for the purpose of any of the methods previously set forth.

20 The attention of the reader is drawn to my simultaneously filed PCT Application (claiming New Zealand priorities from NZ 332084, NZ 332079 and NZ 334471) in which there are disclosed a variety of procedures, methods, pharmaceutical compositions, dosage units etc. involving the use of fructosamine oxidase inhibition and/or antagonism in order to reduce vascular (preferably microvascular) damage to
25 patients (particularly although not solely diabetic or suspected diabetic patients).

Preferably any such inhibitor or antagonist is selected from the groups

- (i) copper chelating agents (eg: triethylenetetramine dihydrochloride, penicillamine, sar, diamsar, ethylenediamine tetraacetic acid, *o*-phenanthroline and histidine)
- 30 (ii) substrate analogues (eg: *N*-acetylcysteine, captopril and enalapril).
- (iii) hydrazine compounds (eg: diaminoguanidine, hydralazine and

carbidopa).

As used herein including the appended claims the term "and/or" means "and" or "or".

The full content of the simultaneously filed PCT International patent
5 specification is hereby included by way of cross reference.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a detailed reaction mechanism for the formation of fructosamine and Maillard products from glucose and protein. Fructosamine oxidase degrades
10 fructosamine by a two-step reaction with initial release of an α -dicarbonyl sugar and subsequent oxidation of the enzyme/protein complex to release free unglycated protein. The reduced copper cofactor is oxidised *in vivo* by molecular oxygen and the oxidation product is superoxide.

Figure 2 shows the relationship between *fructosamine oxidase* measurements and
15 plasma fructosamine. Linear regression equation ($y = 0.0349x - 5.9589$; $r^2 = 0.7455$).

Figure 3 shows the effect of *fructosamine oxidase* inhibitors on enzyme activity in human blood plasma. The three inhibitors are selected, merely by way of example, from the three classes of compounds which inhibit the enzyme (i.e. captopril is a substrate analogue, carbidopa is a hydrazine compound, and potassium cyanide is a
20 copper chelator).

Detailed Description of the Invention

(i) Assay principle

Fructosamine oxidase catalyses the degradation of fructosamine(s) with
25 concurrent reduction of molecular oxygen yielding a superoxide reaction product (FIGURE 1). Superoxide is unstable in aqueous solution with spontaneous dismutation to hydrogen peroxide and oxygen. The dismutation reaction is strongly pH dependent with maximal reactivity in acidic solutions and reducing reactivity in alkaline solution. Therefore, enzyme activity is best determined at pH values 7.0-8.0 and preferably about
30 pH 7.5 where superoxide is more stable using one of the assay compounds listed in Table 1.

TABLE 1

Assay compound	Assay pH	Type of reaction	Reference
Ferricytochrome c	7.8	Reduction	McCord J & Fridovich I. <i>J Biol Chem</i> 244;6087-93 (1969)
Nitroblue tetrazolium	7.8	Reduction	Halliwell B <i>FEBS Lett</i> 72;8 (1976)
Dichlorophenol indophenol	7.0	Reduction	Greenstock CL & Ruddock GW. <i>Int J Radiat Phys Chem</i> 8;367 (1976)
Epinephrine	7.8	Oxidation	Misra HP & Fridovich I <i>J Biol Chem</i> 247;3170-5 (1972)
Hydroxylamine	7.8	Oxidation	Elstner EF, Heupel A. <i>Anal Biochem</i> 70;616-20 (1976)
Peroxidase	7.8	Enzymatic	Misra HP, Fridovich I <i>Anal Biochem</i> 79;553-60 (1977)
NADH...LDH	7.0	Enzymatic	Chan PC & Bielski BHJ. <i>J Biol Chem</i> 249;1317-9 (1974)
NADH...GDH	7.2	Enzymatic	Chan PC & Bielski BHJ. <i>J Biol Chem</i> 255;874-6 (1980)

(ii) Interference

Because superoxide is potentially a noxious substance, superoxide degrading enzyme, superoxide dismutase (SOD), is elaborated in plasma as a physiological response to increasing superoxide concentrations. Compared with healthy non-diabetic individuals, SOD levels are significantly elevated in the plasma of patients with diabetes mellitus and particularly amongst those patients with microvascular disease such as diabetic nephropathy and diabetic retinopathy. See, Mizobuchi N, Nakata H, Horimi T, Takahashi I. *Rinsho Byori* 41;673-8 (1993). The major SOD isoenzyme in extracellular fluids like plasma is extracellular SOD which is a tetrameric glycoprotein that contains four copper atoms and four zinc atoms. See, Karlsson K & Marklund SL *Biochem J* 242;55-9 (1987). Unless it is disabled, such SOD activity will cause significant interference in any blood plasma assay based on the detection systems listed in Table 1.

Almost all of the SOD activity of human plasma is sensitive to inhibition with millimolar concentrations of potassium cyanide, sodium azide or sodium fluoride. Alternatively, SOD activity of plasma may be eliminated by pre-treatment of the plasma sample with anti-human CuZn SOD antisera. See, Marklund SL, Holme E, Hellner L *Clin Chim Acta* 126;41-51 (1982).

(iii) Procedure

Fructosamine oxidase activity may be measured using the redox-active colour reagent, ferricytochrome c, which is readily reduced by superoxide to form ferrocyanochrome c with a characteristic increase in absorbance at 550nm ($\epsilon_{550} = 22.1$ mM⁻¹.cm⁻¹). The reagent is 50mM TES buffer pH 7.4 containing 10µM cytochrome c (Sigma), and 50µM fructosamine as glycated bovine serum albumin. The parameters for performance of the assay in a Cobas Bio (Roche) automated analyser are as shown in Table 2.

TABLE 2

PARAMETER LISTING		
1	UNITS	U/L
2	CALCULATION FACTOR	473.9
3	STANDARD 1 CONCENTRATION	0
4	STANDARD 2 CONCENTRATION	0
5	STANDARD 3 CONCENTRATION	0
6	LIMIT	0
7	TEMPERATURE [DEG.C]	30.0
8	TYPE OF ANALYSIS	6
9	WAVELENGTH [NM]	550
10	SAMPLE VOLUME [UL]	5
11	DILUENT VOLUME [UL]	45
12	REAGENT VOLUME [UL]	200
13	INCUBATION TIME [SEC]	300
14	START REAGENT VOLUME [UL]	25
15	TIME OF FIRST READING [SEC]	0.5
16	TIME INTERVAL [SEC]	300
17	NUMBER OF READINGS	2
18	BLANKING MODE	1
19	PRINTOUT MODE	1

One unit of enzyme was defined as the amount which reduced 1 µmol/minute of cytochrome c in solution under the above assay conditions. The calculation factor is determined from the molar absorptivity for ferrocyanochrome c (ϵ_{550nm}) according to the formula:

$$U/L (\mu\text{mol}.\text{min}^{-1}.\text{L}^{-1}) = TV \times 10^3 / \epsilon_{550} \times SV$$

where TV = total reaction volume

SV = sample volume

(iv) Materials

- 10 -

Glycated bovine serum albumin substrate was prepared as follows:

- (a) Bovine serum albumin (BSA) (Sigma) was reduced with sodium borohydride to eliminate protein hydroperoxides. BSA (60g/L) was dissolved in 0.145M NaCl, pH was adjusted to 9.0 with molar NaOH, sodium borohydride (200mmol/L) was added, and the solution was stirred gently at room temperature for 24 hours. Excess sodium borohydride was discharged with glacial acetic acid and the solution was dialysed exhaustively against 0.145M NaCl at 4 °C.
- (b) Borohydride-reduced BSA was glycated by mixing protein solution with an equal volume 0.4M Na₂PO₄ buffer pH 7.4 containing 50mM glucose and 0.02% sodium azide and incubating at 37 °C for 7 days. Excess glucose was removed by exhaustive dialysis against 0.145M NaCl.
- (c) Glycated BSA (gBSA) was acetylated by adding 0.2M iodoacetic acid, adjusting pH to 6.8, and incubating at room temperature for 24 hours. Excess iodoacetate was removed by exhaustive dialysis against 0.145M NaCl.
- (d) Remaining copper binding sites on gBSA were saturated by dialysing against 0.145M NaCl containing 100µM copper sulphate. Excess copper was removed by exhaustive dialysis against 0.145M NaCl.
- (e) Degree of glycation of gBSA substrate was determined by fructosamine assay (Hoffmann La-Roche).

(v) Substrate specificity

The specificity of the assay for reactive oxygen species was tested by measuring the degree of inhibition of ferricytochrome c reduction after adding the following oxygen free radical scavengers to the reaction mixture: (a) Superoxide dismutase to selectively remove superoxide; (b) catalase to selectively remove hydrogen peroxide; & (iii) mannitol to scavenge hydroxyl radicals. Results are shown in Table 3.

TABLE 3

	Free radical scavenger	Enzyme activity* (U/L)	Significance (P)
	Control	15.34 ± 0.16	-
5	superoxide dismutase (20kU/L)	9.99 ± 0.03	<0.0001
	catalase (1000kU/L)	12.23 ± 0.03	<0.0001
	superoxide dismutase + catalase	6.78 ± 0.12	<0.0001
	mannitol (50mmol/L)	14.96 ± 0.19	0.0421

- 10 • determined with free radical scavenger added to the reagent. Results imply that the assay reaction is measuring both superoxide and hydroxyl radicals formed from the reaction of superoxide with hydrogen peroxide.

(v) Specificity

15 Cytochrome c is a non-specific reductant and other reducing substances in sera or anticoagulants added to the blood sample at specimen collection may interfere in the assay as shown in Table 4.

TABLE 4

	Additive*	Activity compared with control (%)
	Control	100
20	Heparin (1000U/L)	24.4
	EDTA (100µM)	26.3

- Human *fructosamine oxidase* analysed with and without (control) additive in the reagent

25 (vi) Comparison with fructosamine concentrations

Fructosamine oxidase activity was measured in non-diabetic sera and results were compared with serum fructosamine concentrations Figure 2.

(vii) Identifying *fructosamine oxidase* inhibitors

30 An important application of the current activity assay is as a means to identify potential *fructosamine oxidase* antagonists and inhibitors. *Fructosamine oxidase* inhibitors may be hydrazine compounds which bind and block the quinone co-factor, copper chelators which bind and block the copper co-factor, or substrate analogues which mimic the normal substrate of the enzyme. Micromolar amounts of candidate

substance are added to the reaction mixture, and the decrease in *fructosamine oxidase* activity of a human plasma sample is measured. The inhibitory potential of carbidopa (hydrazine compound), potassium cyanide (copper chelator), and captopril (substrate analogue) are demonstrated in FIGURE 3.

- 5 The effectiveness of an enzyme inhibitor is usually expressed by a velocity constant (K) which determines the fraction of the enzyme inhibited in a given period of time by a certain concentration of inhibitor. The specificity of the inhibitor for the active centre of the enzyme is indicated by the concentration of inhibitor causing 50% inactivation of the enzyme (IC_{50}). Results of this *in vitro* assay would suggest that, at
- 10 1 μ M inhibitor concentration, the most effective enzyme inhibitor is carbidopa (K = 15% per minute) followed by captopril (K = 2.6% per minute) followed potassium cyanide (K = 1.2% per minute). Carbidopa also shows the greatest specificity for the active centre of *fructosamine oxidase* ($IC_{50} = 0.50 \mu$ M) compared with captopril ($IC_{50} = 0.83 \mu$ M) and potassium cyanide ($IC_{50} = 6.36 \mu$ M).

15

WHAT WE CLAIM IS:

1. A method of determining fructosamine oxidase activity in blood plasma of mammalian patients or a mammalian patient to determine patients or a patient at risk to vascular damage, which method comprises determining the levels of fructosamine
5 oxidase and/or the superoxide reaction product of fructosamine oxidase and/or any other oxygen free radical product of fructosamine oxidase in the population of patients and making the determination dependant upon such levels.
2. A method of claim 1 wherein the patients are humans suffering from or predisposed to diabetes.
- 10 3. A method of claim 1 or 2 wherein said fructosamine oxidase activity is measured in blood taken from each patient.
4. A method of claim 3 wherein the measurement conducted *in vitro* is of the superoxide reaction product or any other oxygen free radical product of fructosamine oxidase.
- 15 5. A method of any one of the preceding claims wherein at risk patients are or an at risk patient is then treated inter alia to inhibit and/or to antagonise fructosamine oxidase.
6. A method of identifying those individuals who will benefit by treatment with fructosamine oxidase inhibitors and/or antagonists, which method comprises testing an
20 individual or a group of individuals for fructosamine oxidase in their blood directly or by reference to the superoxide reaction product of fructosamine oxidase or any other oxygen free radical product of fructosamine oxidase.
7. A method of claim 6 wherein at risk patients are then treated inter alia to inhibit and/or to antagonise the fructosamine oxidase.
- 25 8. A method of monitoring fructosamine oxidase inhibition and/or antagonism of a patient which comprises or includes testing directly or indirectly the fructosamine oxidase level of such patient.
9. A method of claim 8 wherein such testing is by reference to the superoxide reaction product of fructosamine oxidase any other oxygen free radical product of
30 fructosamine oxidase in the blood of the patient.
10. A method of any one of the preceding claims which involves a determination of a

- particular level attributed to fructosamine oxidase and/or the reaction products referred to in comparison to such level or levels of a patient or patients (as the case may be) who is or are not at risk to such vascular damage, or will not benefit by treatment with fructosamine oxidase inhibitors and/or antagonists or have no need for fructosamine oxidase inhibition and/or antagonism.
11. A method of testing and/or identifying fructosamine oxidase inhibitors or a fructosamine oxidase inhibitor which comprises measuring the effect a candidate substance has or candidate substances have on one or more of the quinone co-factor, the copper co-factor, or at least one substrate analogue of fructosamine oxidase.
12. A method of identifying a candidate substance for trial for the amelioration of diabetes induced vascular damage in a mammal which comprises testing such a substance for fructosamine oxidase inhibition and/or antagonism and choosing to trial the substance where
- (ii) it has a specificity for such an enzyme, or its co-factors,
- and
- (iii) it has an effectiveness for such inhibition and/or antagonism at dosage levels not known to be toxic or contraindicated in such a mammal.
13. The measurement *in vitro* of the superoxide reaction product (and/or any other oxygen free radical product) of fructosamine oxidase in the blood of a mammal by exploiting its reductant properties or its oxidant properties or by enzymatic means.
14. The measurement of claim 13 wherein the procedure involves the disabling of the superoxide scavenging mechanism (such as superoxide dismutase) (SOD) and then exposure to a suitable fructosamine oxidase substrate.
15. The measurement of claim 14 wherein it is made at a pH of 7 to 8.
16. The measurement of claim 15 wherein the pH is at greater than 7.5.
17. The measurement of claim 16 wherein the disabling is by pre-treatment of the plasma sample with anti-human CuZn SOD antisera.
18. The measurement of claim 16 wherein the fructosamine oxidase substrate is glycated bovine serum albumin modified to eliminate copper chelating activity which might diasable the fructosamine oxidase.
19. The measurement of claim 16 which involves measurement of an absorbance

change, chemiluminescent change, or some other characterising change in an indicator of the modified sample.

20. A method of determining the fructosamine oxidase levels in a mammal which involves the measurement as claimed in claim 19.

5 21. A method of determining the blood plasma fructosamine oxidase levels in a diabetic individual or a suspected diabetic individual which involves the measurement procedure of claim 19.

22. A method of assaying blood serum or blood plasma *in vitro* directly and/or indirectly for fructosamine oxidase which involves the measurement procedure of
10 claim 19.

23. A method of claim 11 or 12 which involves a method of any one of claims 13 to 22.

24. A blood serum or blood plasma sample of a patient in which the superoxide scavenging mechanisms therein have been disabled and the pH is in the range from 7
15 to 8.

25. A sample of claim 24 which has been modified by exposure to a suitable fructosamine oxidase substrate.

26. A sample of claim 25 wherein said fructosamine oxidase substrate is glycated bovine serum albumin modified to eliminate copper chelating activity which might
20 disable fructosamine oxidase.

27. The use of a sample as claimed in any one of claims 24 to 26.






FIGURE 1.

2/3

**FIGURE 2.**

3/3

Inhibitors of *fructosamine oxidase* in plasma**FIGURE 3.**

INTERNATIONAL SEARCH REPORT

International application No.
PCT/NZ 99/00160

A. CLASSIFICATION OF SUBJECT MATTER												
Int Cl ⁶ : C12N 9/02, 9/06; C12Q 1/26												
According to International Patent Classification (IPC) or to both national classification and IPC												
B. FIELDS SEARCHED												
Minimum documentation searched (classification system followed by classification symbols) IPC 6												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SEE ELECTRONIC DATABASE BOX BELOW												
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) See extra sheet												
C. DOCUMENTS CONSIDERED TO BE RELEVANT												
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
X A	Marklund, S. L. et al (1982) "Superoxide dismutase in extracellular fluids" <i>Clinica Chimica Acta</i> , 126, 41-51.	24,25										
<input type="checkbox"/> Further documents are listed in the continuation of Box C <input type="checkbox"/> See patent family annex												
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent but published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 15 December 1999		Date of mailing of the international search report 21 DEC 1999										
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer PHILIPPA WYRDEMAN Telephone No.: (02) 6283 2554										

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ 99/00160

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See extra sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ 99/00160

Box

Unity continued:

(1) Claims 1-23, 25-26 and 27 (in part) are directed to the use of fructosamine oxidase or agonists or antagonists of fructosamine oxidase. This is considered a first "special technical feature".

(2) Claims 24 and 27 (in part) are directed to samples wherein superoxide scavenging mechanisms have been disabled. This is considered a second "special technical feature".

These two inventions do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack a common "special technical feature".

Continuation of fields searched:

Search 1.

Fructosamine oxidase, fructosamine (metaloenzyme or oxidoreductase)
C12Q, C12 N

Search 2.

Blood, plasma, serum, superoxide, SOD, superoxide dismutase.